SAB 142
Alternative Names: SAB-142Latest Information Update: 03 Feb 2025
At a glance
- Originator SAB Biotherapeutics
- Developer SAB BIO
- Class Antihyperglycaemics; Immunoglobulins; Polyclonal antibodies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 1 diabetes mellitus
- Discontinued Transplant rejection
Most Recent Events
- 28 Jan 2025 Adverse events and pharmacodynamics data from a phase I trial in Type 1 diabetes mellitus released by SAB BIO
- 28 Jan 2025 SAB Biotherapeutics plans the phase IIb SAFEGUARD trial in Type 1 diabetes mellitus (In adults, In children) (Parenteral) in 2025
- 11 Nov 2024 Discontinued - Preclinical for Transplant rejection in USA (Parenteral) prior to November 2024 (SAB Biotherapeutics pipeline, November 2024)